Skip to content
logo MSD Oncology Clinical Trials
  • Início
  • Estudos
    • Menu principal
    • Visão geral do teste
    • Bexiga
    • Cabeça e Pescoço
    • Colorretal
    • Esofágico
    • Fígado e via Biliar
    • Gástrico
    • Ginecológico
    • Hematológico
    • Mama
    • Melanoma
    • Pediátrico
    • Próstata
    • Pulmão
    • Rim
    • Tumores Sólidos
  • Sobre
  • Perguntas frequentes
  • Para Profissionais Da Saúde
  • Português (BR)
    • Back
    • English
    • English (AU)
    • Español (LatAm)
    • Français (FR)
    • Português (BR)

Therapeutic Area: Tumores Sólidos

This is a 2 part study. Part 1 is a dose escalation to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) dose of MK-0482 administered as monotherapy and in combination with pembrolizumab (MK-3475) in participants with advanced solid tumors for which there is no available therapy which may convey clinical benefit. Part 2 is expansion cohort to determine safety and tolerability of MK-0482 in combination with pembrolizumab with and without chemotherapy in participants with advanced tumor specific cohorts.

Therapeutic Area: Tumores Sólidos

A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

March 10, 2022

By Support_Clique

This is a 2 part study. Part 1 is a dose escalation to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) dose of MK-0482

Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

March 10, 2022

By Tyler Kalist

This is a safety, efficacy, and pharmacokinetics (PK) study of vibostolimab (MK-7684) as monotherapy and in combination with pembrolizumab (MK-3475) or pembrolizumab plus pemetrexed and carboplatin in adults with metastatic solid

Estudo de V937 em combinação com pembrolizumabe em participantes com tumores sólidos avançados/metastáticos

March 7, 2022

By Support_Clique

The purpose of this study is to evaluate the safety, tolerability, and efficacy in participants with advanced/metastatic or recurrent malignancies who receive V937 in Combination with Pembrolizumab (MK-3475). The primary objective

Estudo de pembrolizumabe em participantes pediátricos com tumores sólidos avançados

March 7, 2022

By Support_Clique

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).

Estudo de olaparibe em combinação com pembrolizumabe no tratamento de mutação de reparo de recombinação homóloga e/ou deficiência de recombinação homóloga – Câncer avançado positivo

March 7, 2022

By clique_admin

The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable)

Estudo de quavonlimabe em combinação com pembrolizumabe em tumores sólidos avançados

March 7, 2022

By clique_admin

This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of quavonlimab when used in combination with pembrolizumab in participants with advanced solid tumors.

Eficácia e segurança de olaparibe em participantes com câncer avançado com mutação de reparo ou positivo para deficiência de recombinação homóloga positivo previamente tratado

March 7, 2022

By clique_admin

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to

Eficácia e segurança de pembrolizumabe mais lenvatinibe em participantes com tumores sólidos selecionados previamente tratados

March 7, 2022

By clique_admin

The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer,

logo-white MSD Oncology Clinical Trials
  • Política de privacidade MSD
  • Termos de uso
  • Preferências de cookies
  • Acessibilidade

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

Acessibilidade

Acessibilidade